Cel Sci (CVM) Return on Capital Employed (2011 - 2026)
Cel Sci (CVM) posted Return on Capital Employed of 143.4% for Q1 2026, down 26.15% sequentially from 113.67% in Q4 2025, and down 53.0% YoY from 305.11% in Q1 2025.
Cel Sci (CVM) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cel Sci has reported Return on Capital Employed for 14 years, with the latest figure at 143.4% in Q1 2026.
- Quarterly Return on Capital Employed fell 53.0% year-over-year to 143.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 143.4% (down 53.0% YoY) and the FY2025 annual result came in at 110.54%, down 140.0% from the prior year.
- Return on Capital Employed declined to 143.4% in Q1 2026 per CVM's latest filing, from 113.67% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 59.78% in Q1 2022 and troughed at 161.08% in Q2 2025.
- A 5-year average of 112.87% and a median of 121.82% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed jumped 1592 bps in 2022, then slumped 4829 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 81.47% in 2022, then sank by 50 bps to 122.46% in 2023, then slipped by 5 bps to 128.25% in 2024, then gained by 11 bps to 113.67% in 2025, then retreated by 26 bps to 143.4% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 143.4%, 113.67%, and 129.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -154.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -143.40% |
| Dec 31, 2025 | -113.67% |
| Sep 30, 2025 | -129.79% |
| Jun 30, 2025 | -161.08% |
| Mar 31, 2025 | -142.87% |
| Dec 31, 2024 | -128.25% |
| Sep 30, 2024 | -126.00% |
| Jun 30, 2024 | -128.53% |
| Mar 31, 2024 | -120.25% |
| Dec 31, 2023 | -122.46% |
| Sep 30, 2023 | -121.82% |
| Jun 30, 2023 | -109.99% |
| Mar 31, 2023 | -92.87% |
| Dec 31, 2022 | -81.47% |
| Sep 30, 2022 | -73.53% |
| Jun 30, 2022 | -62.98% |
| Mar 31, 2022 | -59.78% |
| Dec 31, 2021 | -52.29% |
| Sep 30, 2021 | -49.03% |
| Jun 30, 2021 | -61.46% |